原发性开角型青光眼与白内障患者生活质量:iStent inject关键试验中VFQ-25与OSDI分析
该随机对照试验二次分析纳入505例患者,评估iStent inject联合白内障手术与单纯白内障手术对患者报告结局的影响。结果显示iStent inject组在24个月内VFQ-25和OSDI应答者比例均更高,差异受驾驶、眼痛和总体视力等维度影响,且24个月时更多应答者免于用药。
要点
- iStent inject联合白内障手术在24个月内VFQ-25和OSDI应答者比例均高于单纯手术组。
- 驾驶、眼痛和总体视力是VFQ-25中驱动组间差异的主要子量表。
- 24个月时VFQ-25应答者中76.5%免于用药,非应答者为62.5%。
核心结论
- 探索性分析提示,iStent inject联合白内障手术可能通过减少用药依赖,在24个月内较单纯白内障手术改善生活质量。
研究设计与样本
- iStent inject关键试验的随机对照试验二次结局分析,共随机分配505例患者(iStent inject组386例,单纯手术组119例)。
主要发现
- iStent inject组在24个月内所有随访点的PRO应答者比例均更高,VFQ-25复合评分平均58.0% vs 45.8%(P < .05),OSDI复合评分平均56.7% vs 48.9%(P < .05)。
- iStent inject组成为应答者的比值比VFQ-25高60%(P < .05),OSDI高32%(P > .05)。
- VFQ-25子量表中驾驶(49.0% vs 28.8%;P < .05)、眼痛(59.3% vs 47.2%;P < .05)和总体视力(71.8% vs 60.0%;P < .05)是组间差异来源。
- 第24个月时,无论治疗分组,76.5%的VFQ-25应答者和62.5%的非应答者免于用药(P < .05)。
关键数值与推荐
- PRO应答者定义为达到基于最小重要差异的改善。
- VFQ-25和OSDI问卷在基线及第1、6、12、24个月 administered。
临床怎么用
- 对于原发性开角型青光眼合并白内障患者,iStent inject联合白内障手术可能通过减少用药依赖改善生活质量,尤其关注驾驶、眼痛和总体视力相关结局。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess quality of life (QOL) as measured by patient-reported outcomes (PRO) within the iStent inject® pivotal trial. DESIGN: Randomized controlled trial analysis of secondary outcomes. METHODS: The Vision Function Questionnaire (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaire were administered at baseline and at months 1, 6, 12, and 24. PRO responders were defined as patients reaching improvement based on minimally important differences. RESULTS: A total of 505 patients were randomized (386 iStent inject® [Glaukos], 119 surgery alone). The iStent inject® group exhibited a greater percentage of PRO responders across all follow-up visits over 24 months, averaging 58.0% vs 45.8%; P < .05 for VFQ-25 composite scores and 56.7% vs 48.9%; P < .05 for OSDI composite scores. Odds of being a responder in the iStent inject® group was 60% (P < .05) higher for the VFQ-25 and 32% (P > .05) higher for the ODSI. Driving (49.0% vs 28.8%; P < .05), ocular pain (59.3% vs 47.2%; P < .05), and general vision (71.8% vs 60.0%; P < .05) were the VFQ-25 subscales responsible for differences between treatment groups. At month 24, 76.5% of VFQ-25 responders and 62.5% of nonresponders were medication free regardless of treatment group (P < .05). CONCLUSIONS: Exploratory analysis suggests that by reducing medication dependence, implantation with the micro-scale iStent inject® device with cataract surgery may improve QOL vs cataract surgery alone over 24 months, with improvements influenced by ocular symptoms and vision-related activities.
引用
- Samuelson TW, Singh IP, Williamson BK, et al. Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI From the iStent inject® Pivotal Trial. Am J Ophthalmol. 2021. PMID: 33737036. doi:10.1016/j.ajo.2021.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。